Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Inovio Pharmaceuticals (INO) PT Raised to $14 at RBC Capital
March 15, 2018 8:25 AM EDTRBC Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining an Outperform rating.
Analyst Gregory Renza notes the pipeline continues to progress as VGX-3100 continues to ramp up with broad CIN site expansion.
... MoreInovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV
March 14, 2018 8:10 AM EDTInovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the clinical study. Preliminary immunology data from the trial revealed that treatment of patients with INO-1800 resulted in the generation of T cells that recognized key components of the hepatitis B virus and reacted by making antiviral cytokines such as Interferon gamma, a protein believed to be linked to clearance of HBV... More
